Cargando…
Impact of Arterial Stiffness on All-Cause Mortality in Patients Hospitalized With COVID-19 in Spain
Older age and cardiovascular comorbidities are well-known risk factors for all-cause mortality in patients with coronavirus disease 2019 (COVID-19). Hypertension and age are the 2 principal determinants of arterial stiffness (AS). This study aimed to estimate AS in patients with COVID-19 requiring h...
Autores principales: | Rodilla, Enrique, López-Carmona, Maria Dolores, Cortes, Xavi, Cobos-Palacios, Lidia, Canales, Sergio, Sáez, Maria Carmen, Campos Escudero, Samara, Rubio-Rivas, Manuel, Díez Manglano, Jesus, Freire Castro, Santiago J., Vázquez Piqueras, Nuria, Mateo Sanchis, Elisabeth, Pesqueira Fontan, Paula Maria, Magallanes Gamboa, Jeffrey Oskar, González García, Andrés, Madrid Romero, Victor, Tamargo Chamorro, Lara, González Moraleja, Julio, Villanueva Martínez, Javier, González Noya, Amara, Suárez-Lombraña, Ana, Gracia Gutiérrez, Anyuli, López Reboiro, Manuel Lorenzo, Ramos Rincón, José Manuel, Gómez Huelgas, Ricardo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884247/ https://www.ncbi.nlm.nih.gov/pubmed/33377393 http://dx.doi.org/10.1161/HYPERTENSIONAHA.120.16563 |
Ejemplares similares
-
Estimation of Admission D-dimer Cut-off Value to Predict Venous Thrombotic Events in Hospitalized COVID-19 Patients: Analysis of the SEMI-COVID-19 Registry
por: García-Cervera, Carles, et al.
Publicado: (2021) -
Clinical Characteristics and Risk Factors of Respiratory Failure in a Cohort of Young Patients Requiring Hospital Admission with SARS-CoV2 Infection in Spain: Results of the Multicenter SEMI-COVID-19 Registry
por: Díaz-Simón, Raquel, et al.
Publicado: (2021) -
COVID-19 and Argumentum ad ignorantiam or “not everything goes”()
por: López Reboiro, M.L., et al.
Publicado: (2020) -
Réplica: Ivermectina en COVID-19. ¿Argumentum ad ignorantiam?
por: López Reboiro, M.L., et al.
Publicado: (2020) -
Reply to: Ivermectin in COVID-19. Argumentum ad ignorantiam?()
por: López Reboiro, M.L., et al.
Publicado: (2020)